Chinese biotech firm Adagene plans $200m US IPO

Chinese biotech firm Adagene plans $200m US IPO

Adagene is a clinical stage oncology-based biotech company

Adagene Inc., a Chinese biotechnology company backed by WuXi AppTec Co. and private equity firm General Atlantic, is planning a U.S. initial public offering that could raise about $200 million, according to people familiar with the matter.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter